Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Treatment options for ADHD in the Netherlands have increased with the introduction of the extended-release formulations of methylphenidate (MPH ER, Concerta(®)) in 2003 and atomoxetine (ATX, Strattera(®)) in 2005, but data on the effect on drug usage patterns are scarce. The objective of the present study was to describe changes in the patterns of ADHD medication use and determinants thereof among children, adolescents and adults (<45 years) starting ADHD medication since the introduction of MPH ER and ATX. Data were obtained from Dutch community pharmacies as collected by the Foundation for Pharmaceutical Statistics, covering 97% of all dispenses for prescription medicines to outpatients in the Netherlands. Usage patterns (continuation, discontinuation, switching and addition) of ADHD drugs were evaluated at 3, 6 and 12 months after initiation for three separate time cohorts (patients starting ADHD medication in Jan-Dec 2002, Jan 2003-June 2004, respectively July 2004-Dec 2005). It was found that between 2002 and 2006, most ADHD drug users were initiated on methylphenidate IR. Discontinuation of any ADHD drug treatment decreased over time partly in favour of switching and addition. Discontinuation at 3 months decreased from around 33% to around 25%, at 6 months from less than 50% to almost 35%, and at 12 months from just fewer than 60% to less than 45%. Discontinuation was higher among females and in adults >18 years. After the introduction of MPH ER and ATX (time cohort III), 16.5% of the incident ADHD drug users switched their medication and almost 9% added an ADHD drug to the prior ADHD drug. In conclusion, discontinuation of incident ADHD drug use is high after 3, 6 and 12 months. During the study period, the incidence of discontinuation decreased because of the availability of extended-release methylphenidate and atomoxetine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FARAONE, S. V., BIEDERMAN, J., & MICK, E. (2006) · Psychological Medicine · doi:10.1017/s003329170500471x · Cited by 2,267
Mannuzza, S. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820190067007 · Cited by 1,368 · cited 1×
“Untreated ADHD is a risk factor for traffic accidents, emergency room visits, school, work and marital problems, substance abuse and psychopathology (Fischer et al. 1990; Barkley et al. 1993, 1996; Mannuzza et al. 1993; DiScala et al.1998; Leibson et al. 2001; Wilens 2004; Sobanski et al. 2008a, b).”
BackgroundGreenhill, L. L., Pliszka, S., & Dulcan, M. K. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200202001-00003 · Cited by 927
Trends in the Prescribing of Psychotropic Medications to Preschoolers
Zito, J. M. (2000) · JAMA · doi:10.1001/jama.283.8.1025 · Cited by 863 · cited 1×
“…the last two decades in prevalence and incidence in the use of ADHD medication among preschoolers, children and adults (Robison et al. 1999, 2005; Zito et al. 2000, 2007, 2008; Miller et al. 2001; Schirm et al. 2001; Reid et al. 2002; DeBar et al. 2003; Hugtenburg et al. 2005; DosReis et al.…”
BackgroundSpencer, T., Biederman, J., Wilens, T., Doyle, R., Surman, C., Prince, J., Mick, E., Aleardi, M., Herzig, K., & Faraone, S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.043 · Cited by 385 · cited 1×
“…Parameter for the use of stimulant medications in the treatment of children, adolescents and adults 2002; Multidisciplinaire Richtlijn ADHD 2005) and adults (Kooij 2003; Spencer et al. 2005), it can also be prescribed to adults for somatic problems (Donker et al. 2005; Gagnon et al. 2005).”
BackgroundBarkley, R. A., Murphy, K. R., & Kwasnik, D. (1996) · Pediatrics · doi:10.1542/peds.98.6.1089 · Cited by 375
Stimulant Treatment for Children: A Community Perspective
ANGOLD, A., ERKANLI, A., EGGER, H. L., & COSTELLO, E. J. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200008000-00009 · Cited by 353 · cited 1×
“US data have suggested that the average duration of psychostimulant use ranges from 5 years for middle school students (Safer and Krager 1994; Angold et al. 2000) to 8 years for high school students.”
BackgroundKessler, R. C., Adler, L., Ames, M., Barkley, R. A., Birnbaum, H., Greenberg, P., Johnston, J. A., Spencer, T., & ??st??n, T. B. (2005) · Journal of Occupational and Environmental Medicine · doi:10.1097/01.jom.0000166863.33541.39 · Cited by 335
Injuries to children with attention deficit hyperactivity disorder
DiScala, C., Lescohier, I., Barthel, M., & Li, G. (1998) · PEDIATRICS · doi:10.1542/peds.102.6.1415 · Cited by 305
A three-country comparison of psychotropic medication prevalence in youth
Zito, J. M., Safer, D. J., Berg, L. T. D. J.-V. D., Janhsen, K., Fegert, J. M., Gardner, J. F., Glaeske, G., & Valluri, S. C. (2008) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-2-26 · Cited by 201
Continuity of Methylphenidate Treatment for Attention-Deficit/Hyperactivity Disorder
Marcus, S. C., Wan, G. J., Kemner, J. E., & Olfson, M. (2005) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.159.6.572 · Cited by 163 · cited 2×
“In children (6–17 year) and adults, initial use of MPH ER was associated with a longer duration of treatment compared to the initial use of MPH IR (Lage and Hwang 2004; Marcus et al. 2005; Olfson et al. 2007).”
Result
Cited by
López, F. A., & Leroux, J. R. (2013) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-013-0106-x · Cited by 43
Berek, M., Kordon, A., Hargarter, L., Mattejat, F., Slawik, L., Rettig, K., & Schäuble, B. (2011) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-5-26 · Cited by 15
Combined Medication with Stimulants and Non-Stimulants for Attention-Deficit/Hyperactivity Disorder
Bahn, G. H., & Seo, K. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.4.705 · Cited by 8
Metadata
- Authors
- van den Ban, E., Souverein, P. C., Swaab, H., van Engeland, H., Egberts, T. C. G., & Heerdink, E. R.
- Venue
- ADHD Attention Deficit and Hyperactivity Disorders
- Published
- 2010-11-30
- Volume
- 2
- Issue
- 4
- Pages
- 213-220
- ISSN
- 1866-6116 (ISSN-L)
- 1866-6647
- OpenAlex
- W2003911018
- Cited by
- 39
- References
- 11
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.